CURE continues to be an important supporter of the Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta and Winship Cancer Institute at Emory University as well as other leading pediatric cancer research institutions across the nation. Through generosity of donors, CURE is able to provide more than $3 million in annual support to promising research projects.

For the current fiscal year, we are funding 25 specific projects (up from 19 in the preceding year), most of which focus on finding effective treatments for the 20% of kids not surviving today’s methods. We also fund the training of three future pediatric oncologists and researchers through the fellowship program at Emory University School of Medicine.

Research Projects

Aflac Cancer and Blood Disorders Center at Children’s Healthcare of Atlanta

Thomas Cash, MD, MSc

For the proposal entitled A Phase I Study of 131I-MIBG with Dinutuximab for Relapsed/Refractory

Robert C. Castellino & Dolores Hambardzumyan

For the proposal entitled The Functional Role of Mutated PPM1D in Radiation Response of DIPGs

Kelly Goldsmith, MD

For the proposal entitled Targeting YAP and RAS/MAPK signaling to enhance survival in relapsed high-risk neuroblastoma

Doug Graham and Deborah DeRyckere

For the proposal entitled MerTK Inhibitor Combination Therapy for Treatment of AML

Lubing Gu, MD (PI) and Muxiang Zhou, MD, (Co-PI)

For the proposal entitled MDM4-TOP2A interaction as potential target for treatment of pediatric cancers

Anna Marie Kenney, PhD

For the proposal entitled Regulating YAP1-YB1 interaction to target medulloblastoma growth

Jordan Gilleland Marchak, PhD, ABPP

For the proposal entitled Evaluating Patient Engagement in Survivor-focused Healthcare after Childhood Cancer Treatment

Lillian R. Meacham, MD

For the proposal entitled Addressing Infertility Related Knowledge Gaps and Needs of Adolescent and Young Adult (AYA) Survivors of Childhood Cancer

Cheng-Kui Qu, MD, PhD.

For the proposal entitled Targeting leukemic stem cells in acute myeloid leukemia

Himalee Sabnis, MD, MSc

For the proposal entitled ENCERT: A Phase 1 Trial using Everolimus in combination with Nelarabine, Cyclophosphamide and Etoposide in Relapsed T cell Lymphoblastic Leukemia/Lymphoma

Cynthia Wetmore, MD, PhD

For the Phase I study of Abemaciclib (Cdk 4/6 inhibitor) in children with newly diagnosed diffuse intrinsic pontine glimoa and in recurrent solid tumors including malignant brain tumors

Jim Felker, MD

Fellowship program

Ryan Summers, MD

Fellowship program

Winship Cancer Institute at Emory University

Erwin G. Van Meir, PhD

For the proposal entitled Investigating the tumor suppressor role of BAI3 in medulloblastoma

Renee Read, Ph.D.

For the proposal entitled YAP/TAZ inhibition in pediatric high-grade gliomas

Hui-Kuo G. Shu, MD, PhD

For the proposal entitled Id1 inhibition as a novel strategy for treatment of glioblastomas

Children’s Hospital of Richmond/Massey Cancer Center at VCU

Seth J. Corey

For the proposal entitled Targeting Monosomy 7 Myeloid Malignancy.

 
 

Children’s Hospital of Philadelphia

Kathryn Black, PhD

For the proposal entitled Targeting alternative splicing of CD19 in relapsed pediatric acute lymphoblastic leukemia to promote susceptibility to immunotherapy

Michael Chorny, PhD

For the proposal entitled Targeted Neuroblastoma Pharmacotherapy Using Nanocarriers

 

Dana-Farber Cancer Institute

Steven DuBois, MD MS

For the Phase 1 Trial of Dual PI3K/BRD4 Inhibitor for Children with Neuroblastoma

 
 

Children’s Cancer Therapy Development Institute:

Charles Keller

For the proposal entitled “CUREfast: Accelerating Research with Families;” Cancer Registry for Familial and Sporadic Tumors

 
 

Memorial Sloan Kettering Cancer Center

Hans-Guido Wendel

For the proposal entitled The eIF4A RNA helicase is a new drug target in relapsed T-ALL

Sara Zarnegar, MD

For the proposal entitled Characterization of a novel xenotransplantation model to identify therapeutic vulnerabilities in MLL-rearranged leukemia

 

Seattle Children’s Hospital

Leslie Kean, MD

For the proposal entitled A First-in-Disease Phase II Trial of T cell Costimulation Blockade for GVHD Prevention

 
 

University of Utah

Kevin B. Jones

For the proposal entitled Genomic categorization of clear cell sarcomagenesis to guide therapeutic investigation

 
 

Children’s Cancer Therapy Development Institute

Charles Keller

For the proposal entitled “CUREfast: Accelerating Research with Families;” Cancer Registry for Familial and Sporadic Tumors

 
 

Join Our Newsletter

Subscribe